<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for fatigue in peripheral neuropathy - White, CM - 2014 | Cochrane Library</title> <meta content="Interventions for fatigue in peripheral neuropathy - White, CM - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008146.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for fatigue in peripheral neuropathy - White, CM - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008146.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008146.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for fatigue in peripheral neuropathy" name="citation_title"/> <meta content="Claire M White" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Claire.white@kcl.ac.uk" name="citation_author_email"/> <meta content="Pieter A van Doorn" name="citation_author"/> <meta content="Erasmus University Medical Center" name="citation_author_institution"/> <meta content="Marcel PJ Garssen" name="citation_author"/> <meta content="Jeroen Bosch Hospital And Erasmus Medical Centre" name="citation_author_institution"/> <meta content="Rachel C Stockley" name="citation_author"/> <meta content="Elizabeth Gaskell Campus" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD008146.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/12/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008146.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008146.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008146.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amantadine [adverse effects, *therapeutic use]; Ascorbic Acid [adverse effects, *therapeutic use]; Charcot‐Marie‐Tooth Disease [*complications]; Fatigue [etiology, *therapy]; Guillain‐Barre Syndrome [*complications]; Peripheral Nervous System Diseases [complications]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008146.pub2&amp;doi=10.1002/14651858.CD008146.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008146\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008146\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008146.pub2",title:"Interventions for fatigue in peripheral neuropathy",firstPublishedDate:"Dec 18, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008146.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008146.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008146.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008146.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008146.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008146.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008146.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008146.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008146.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008146.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5121 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008146.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/appendices#CD008146-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/table_n/CD008146StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/table_n/CD008146StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for fatigue in peripheral neuropathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#CD008146-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Claire M White</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#CD008146-cr-0003">Pieter A van Doorn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#CD008146-cr-0004">Marcel PJ Garssen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information#CD008146-cr-0005">Rachel C Stockley</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information/en#CD008146-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 December 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008146.pub2">https://doi.org/10.1002/14651858.CD008146.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008146-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008146-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008146-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008146-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008146-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD008146-abs-0009">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008146-abs-0001" lang="en"> <section id="CD008146-sec-0001"> <h3 class="title" id="CD008146-sec-0001">Background</h3> <p>Persistent feelings of fatigue (or subjective fatigue), which may be experienced in the absence of physiological factors, affect many people with peripheral neuropathy. A variety of interventions for subjective fatigue are available, but little is known about their efficacy or the likelihood of any adverse effects for people with peripheral neuropathy. </p> </section> <section id="CD008146-sec-0002"> <h3 class="title" id="CD008146-sec-0002">Objectives</h3> <p>To assess the effects of drugs and physical, psychological or behavioural interventions for fatigue in adults or children with peripheral neuropathy. </p> </section> <section id="CD008146-sec-0003"> <h3 class="title" id="CD008146-sec-0003">Search methods</h3> <p>On 5 November 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, CINAHL Plus, LILACS and AMED. We also searched reference lists of all studies identified for inclusion and relevant reviews, and contacted the authors of included studies and known experts in the field to identify additional published or unpublished data. We also searched trials registries for ongoing studies. </p> </section> <section id="CD008146-sec-0004"> <h3 class="title" id="CD008146-sec-0004">Selection criteria</h3> <p>We considered for inclusion randomised controlled trials (RCTs) and quasi‐RCTs comparing any form of intervention for fatigue management in adults with peripheral neuropathy with placebo, no intervention or an alternative form of intervention for fatigue. Interventions considered included drugs, pacing and grading of physical activity, general or specific exercise, compensatory strategies such as orthotics, relaxation, counselling, cognitive and educational strategies. </p> </section> <section id="CD008146-sec-0005"> <h3 class="title" id="CD008146-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed risk of bias and extracted study data. We contacted study authors for additional information. We collected information on adverse events from the included trials. </p> </section> <section id="CD008146-sec-0006"> <h3 class="title" id="CD008146-sec-0006">Main results</h3> <p>The review includes three trials, which were all at low risk of bias, involving 530 people with peripheral neuropathy. The effects of amantadine from one randomised, double‐blind, placebo‐controlled, cross‐over trial comparing amantadine with placebo for the treatment of fatigue in 80 people with Guillain‐Barré syndrome (GBS) were uncertain for the proportion of people achieving a favourable outcome six weeks post‐intervention (odds ratio (OR) 0.56 (95% confidence interval (CI) 0.22 to 1.35, N = 74, P = 0.16). We assessed the quality of this evidence as low. Two parallel‐group randomised double‐blind, placebo‐controlled trials comparing the effects of two doses of ascorbic acid with placebo for reducing fatigue in adults with Charcot‐Marie‐Tooth disease type 1A (CMT1A) showed that the effects of ascorbic acid at either dose are probably small (standardised mean difference (SMD) ‐0.12 (95% CI ‐0.32 to 0.08, n = 404, P = 0.25)) for change in fatigue after 12 to 24 months (moderate quality evidence). Neither ascorbic acid study measured fatigue at four to 12 weeks, which was our primary outcome measure. No serious adverse events were reported with amantadine. Serious adverse events were reported in the trials of ascorbic acid. However,risk of serious adverse events was similar with ascorbic acid and placebo. </p> </section> <section id="CD008146-sec-0007"> <h3 class="title" id="CD008146-sec-0007">Authors' conclusions</h3> <p>One small imprecise study in people with GBS showed uncertain effects of amantadine on fatigue. In two studies in people with CMT1A there is moderate‐quality evidence that ascorbic acid has little meaningful benefit on fatigue. Information about adverse effects was limited, although both treatments appear to be well tolerated and safe in these conditions. </p> <p>There was no evidence available from RCTs to evaluate the effect of other drugs or other interventions for fatigue in either GBS, CMT1A or other causes of peripheral neuropathy. The cost effectiveness of different interventions should also be considered in future randomised clinical trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008146-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008146-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008146-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008146-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008146-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD008146-abs-0010">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008146-abs-0004" lang="en"> <h3>Treatments for fatigue in peripheral neuropathy</h3> <p><b>Review question</b> </p> <p>To assess the effects of treatments for fatigue in people with peripheral neuropathy.</p> <p><b>Background</b> </p> <p>Peripheral neuropathy is damage to the nerves outside the brain and spinal cord. Many people with peripheral neuropathy have feelings of severe tiredness (fatigue) that are not necessarily related to physical problems such as muscle weakness. Evidence in other long‐term illnesses where fatigue is a problem suggests that medicines and other forms of treatment may help. The aim of this review was to assess the effect of drugs and other treatments, such as general or specific exercise, orthotics (devices such as braces), relaxation, counselling and cognitive, behavioural and educational strategies on feelings of fatigue in people with peripheral neuropathy. </p> <p><b>Study characteristics</b> </p> <p>From a wide search, we identified three RCTs that met our selection criteria. The trials involved a total of 530 adults with peripheral neuropathy. Treatments were ascorbic acid (vitamin C) in people with Charcot‐Marie‐Tooth disease in two trials, and amantadine in Guillain‐Barré syndrome in the third. Charcot‐Marie‐Tooth disease is an inherited nerve disease and Guillain‐Barré syndrome is a condition where there is inflammation of the peripheral nerves. We chose measures of fatigue at four to 12 weeks as our preferred measure of the effects of treatment. The amantadine trial but not the ascorbic acid trials provided data at this time point; the ascorbic acid trials provided data more than 12 months after the start of the intervention. </p> <p><b>Key results and quality of the evidence</b> </p> <p>There was insufficient evidence to determine the effects of amantadine when compared with an inactive treatment (placebo) for fatigue. and there were no major unwanted effects. We found evidence that ascorbic acid probably has little meaningful benefit for fatigue. No major unwanted effects were identified, but the trials were small. We assessed the quality of this evidence as moderate because the results were imprecise, which means they do not rule out the possibility that the drugs could have an effect. We found no evidence from RCTs on other medicines or treatments for fatigue in peripheral neuropathy. </p> <p>There is insufficient evidence to determine the effect of amantadine for fatigue in GBS and ascorbic acid for fatigue in CMT1A. More high‐quality studies are needed to provide evidence on which to base management of feelings of fatigue in peripheral neuropathy. The cost effectiveness of different interventions should also be considered in future RCTs. </p> <p>The evidence in this review is current to November 2013.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008146-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008146-sec-0093"></div> <h3 class="title" id="CD008146-sec-0094">Implications for practice</h3> <section id="CD008146-sec-0094"> <p>The evidence from randomised controlled trials of the efficacy of interventions for fatigue in peripheral neuropathy is limited. One small study comparing amantadine with placebo for fatigue in people with Guillain‐Barré syndrome was not sufficiently powered to determine the effects on fatigue in this population. There was moderate quality evidence that the effects of ascorbic acid on fatigue in people with Charcot‐Marie‐Tooth disease 1A are small. Information about adverse effects was limited, although both treatments appeared to be well tolerated in these conditions. </p> <p>There was no evidence available from randomised controlled trials to evaluate the effect of other interventions for fatigue in either Guillain‐Barré syndrome, Charcot‐Marie‐Tooth disease 1A or other causes of peripheral neuropathy. </p> </section> <h3 class="title" id="CD008146-sec-0095">Implications for research</h3> <section id="CD008146-sec-0095"> <p>The dearth of evidence from high‐quality randomised controlled trials on the effects of interventions for fatigue in peripheral neuropathy indicates that treatments for this condition warrant further research. Trials in relevant patient populations should have adequate sample size, appropriate randomised controlled designs and clinically relevant standardised and responsive measures of fatigue as an outcome. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008146-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008146-sec-0029"></div> <div class="table" id="CD008146-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Amantadine versus placebo for fatigue in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Amantadine versus placebo for fatigue in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fatigue in Guillain‐Barré syndrome<br/> <b>Settings:</b> <br/> <b>Intervention:</b> amantadine versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Amantadine </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in fatigue of at least 1‐point on the Fatigue Severity Scale between 4 to 12 weeks after commencement of intervention</b> <br/> Fatigue Severity Scale (FSS) from 1 to 7 (higher score is worse)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b> <br/> (71 to 318) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.56</b> <br/> (0.22 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 cross‐over study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in fatigue 12 or more weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in activity limitation 12 or more weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in participation 12 or more weeks after commencement of intervention using the</b> <br/> Rotterdam Handicap Scale. Scale from: 0 to 36.<br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in participation 12 or more weeks after commencement of intervention using the control group was<br/> <b>0.34 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in participation 12 or more weeks after commencement of intervention using the intervention group was<br/> <b>0.31 higher</b> <br/> (0.09 lower to 0.72 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 cross‐over study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health related quality of life after 12 or more weeks or more after commencement of intervention</b> (not reported) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EHQ and SF‐36 measured but data not fully reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 cross‐over study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 participants had serious adverse events in this study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded two levels due to imprecision (small sample size and wide CI that crosses the line of no effect). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008146-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ascorbic acid versus placebo for fatigue in peripheral neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ascorbic acid versus placebo for fatigue in peripheral neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fatigue in peripheral neuropathy<br/> <b>Settings:</b> <br/> <b>Intervention:</b> ascorbic acid versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ascorbic acid </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reduction in fatigue of at least 1 point on the Fatigue Severity Scale (FSS) between 4 to 12 weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in fatigue 12 or more weeks after commencement of intervention</b> <br/> Visual Analogue Scale (VAS) of fatigue<br/> Follow‐up: mean 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue 12 or more weeks after commencement of intervention in the intervention groups was<br/> <b>0.12 standard deviations lower</b> <br/> (0.32 lower to 0.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in activity limitation (ODSS/ONLS) 12 or more weeks after commencement of intervention</b> <br/> Overall Neuropathy Limitations Scale or Overall Disability Sum Score. Scale from: 0 to 12.<br/> Follow‐up: 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data available were not suitable for meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in 10 metre timed walk 12 or more weeks after commencement of intervention</b> <br/> Time taken to walk 10 metres in seconds<br/> Follow‐up: 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean changes in 10 metre timed walk 12 or more weeks after commencement of intervention in the control groups were<b>a decrease of 0.40 seconds and an increase of 0.76 seconds</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 10 metre timed walk 12 or more weeks after commencement of intervention in the intervention groups was <b>a decrease of</b> <br/> <b>0.39 seconds</b> (1.04 faster to 0.26 slower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in speed of completion of 9‐hole peg test (in seconds) 12 or more weeks after commencement of intervention</b> <br/> Time (in seconds) taken to complete 9‐hole peg test<br/> Follow‐up: mean 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in speed of completion of the 9‐hole peg test was an <b>increase of 0.85 seconds</b> in the control group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in speed of completion of the 9‐hole peg test was <b>a decrease of 0.74 seconds</b> </p> <p>(1.60 faster to 0.12 slower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life 12 or more weeks after commencement of the intervention</b> </p> <p><b>Change in SF‐36 physical function score</b> <br/> SF‐36 Physical Functioning Scale and Physical Component Score<br/> Follow‐up: 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life 12 or more weeks after commencement of the intervention (change in SF‐36 physical function score) in the intervention groups was<br/> <b>0.08 standard deviations higher</b> <br/> (0.12 lower to 0.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in participation 12 or more weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life 12 or more weeks after commencement of the intervention Change in mental function score of SF‐36</b> <br/> SF‐36 Mental Component Score<br/> Follow‐up: mean 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in health‐related quality of life 12 or more weeks after commencement of the intervention (change in mental function score of SF‐36) in the control group was <b>1.2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life 12 or more weeks after commencement of the intervention (change in mental function score of SF‐36) in the intervention groups was<br/> <b>0.9 higher</b> <br/> (2.65 lower to 4.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> <br/> (42 to 137) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> <br/> (0.39 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Only one or two studies included.<br/> <sup>2</sup> Assumed control group risks are the control group values in the two trials. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008146-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008146-sec-0030"></div> <section id="CD008146-sec-0031"> <h3 class="title" id="CD008146-sec-0031">Description of the condition</h3> <p>Peripheral neuropathies collectively affect about 2.4% of the population and may be either genetic or acquired, and either acute or chronic in nature (<a href="./references#CD008146-bbs2-0045" title="MartynC , HughesRAC . Peripheral neuropathies. The Epidemiology of Neurological Disorders. 1st Edition. London: BMJ, 1998. ">Martyn 1998</a>). The pathological process affects peripheral nerves, resulting in neurological damage to either the axon (ie, degeneration of the central nerve fibre), the myelin (ie, demyelination or destruction of the insulating sheath of the nerve), or a combination of both. Recovery may be by remyelination, through which improvements in function can be rapid, and in some people there is almost complete recovery. However, regeneration of damaged axons usually takes many months or years and recovery, if present, may be incomplete (<a href="./references#CD008146-bbs2-0058" title="TamuraN , KuwabaraS , MisawaS , KanaiK , NakataM , SawaiS , et al. Time course of axonal regeneration in acute motor axonal neuropathy. Muscle &amp; Nerve2007;35(6):793‐5. ">Tamura 2007</a>). </p> <p>Common symptoms of peripheral neuropathy include numbness, diminished or altered sensation (pins and needles), muscle weakness, and autonomic dysfunction. People may also experience fatigue, pain, psychological dysfunction and poor social adjustment (<a href="./references#CD008146-bbs2-0043" title="LennonSM , KoblarS , HughesRAC , GoellerJ , RiserAC . Reasons for persistent disability in Guillain‐Barré syndrome. Clinical Rehabilitation1993;7(1):1‐8. ">Lennon 1993</a>; <a href="./references#CD008146-bbs2-0049" title="PfeifferG , WickleinEM , RatusinskiT , SchmittL , KunzeK . Disability and quality of life in Charcot‐Marie‐Tooth disease type 1. Journal of Neurology, Neurosurgery and Psychiatry2001;70(4):548‐50. ">Pfeiffer 2001</a>). Even when neurological function improves, residual symptoms often persist and fatigue is frequently an ongoing problem (<a href="./references#CD008146-bbs2-0046" title="MerkiesIS , SchmitzPI , SamijnJP , van derMechéFG , vanDoornPA . Fatigue in immune‐mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology1999;53(8):1648‐54. ">Merkies 1999</a>). </p> <p>The experience of fatigue (or subjective fatigue) has been described as a "an overwhelming sense of tiredness, lack of energy and feeling of exhaustion" that is "not relieved by rest" and is a common sequel of chronic conditions (<a href="./references#CD008146-bbs2-0015" title="BleijenbergG . Chronic fatigue and chronic fatigue syndrome in the general population. Health and Quality of Life Outcomes2003;1:52. ">Bleijenberg 2003</a>; <a href="./references#CD008146-bbs2-0037" title="KarlsenK , LarsenJP , TandbergE , JorgensenK . Fatigue in patients with Parkinson's disease. Movement Disorders1999;14(2):237‐41. ">Karlsen 1999</a>; <a href="./references#CD008146-bbs2-0041" title="KruppLB . Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs2003;17(4):225‐34. ">Krupp 2003</a>). Physiological fatigue, or "the loss of voluntary force‐producing capacity during exercise" (<a href="./references#CD008146-bbs2-0014" title="Bigland‐RitchieB , JonesDA , HoskingGP , EdwardsRH . Central and peripheral fatigue in sustained maximum voluntary contractions of human quadriceps muscle. Clinical Science and Molecular Medicine1978;54(6):609‐14. ">Bigland‐Ritchie 1978</a>) can contribute to subjective fatigue, but people can experience subjective fatigue in the absence of physiological factors and physiological fatigue does not necessarily result in subjective fatigue.<br/> <br/> Physical factors such as residual muscle weakness mean that people with peripheral neuropathy have to work harder during everyday activities than healthy individuals, which will feel more of an effort. Axonal degeneration prevents nerve impulses from being conducted along the peripheral nerve and demyelination can lead to conduction block that can be exacerbated by muscle activity (<a href="./references#CD008146-bbs2-0017" title="Cappelen‐SmithC , KuwabaraS , LinCS , MogyorosI , BurkeD . Activity‐dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology2000;48(6):826‐32. ">Cappelen‐Smith 2000</a>), leading to fatigue (<a href="./references#CD008146-bbs2-0036" title="KajiR , BostockH , KoharaN , MuraseN , KimuraJ , ShibasakiH . Activity‐dependent conduction block in multifocal motor neuropathy. Brain2000;123(Pt 8):1602‐11. ">Kaji 2000</a>). Although there is no direct problem with the muscles themselves, it has been shown that people with peripheral neuropathy may be unable to voluntarily activate their muscles fully, possibly because of dysfunction within the central nervous system (<a href="./references#CD008146-bbs2-0028" title="GarssenMP , SchillingsML , vanDoornPA , vanEngelenBG , ZwartsMJ . Contribution of central and peripheral factors to residual fatigue in Guillain‐Barré syndrome. Muscle &amp; Nerve2007;36(1):93‐9. ">Garssen 2007</a>; <a href="./references#CD008146-bbs2-0055" title="SchillingsML , HoefslootW , StegemanDF , ZwartsMJ . Relative contributions of central and peripheral factors to fatigue during a maximal sustained effort. European Journal of Applied Physiology2003;90(5‐6):562‐8. ">Schillings 2003</a>). This form of physiological fatigue is known as central fatigue and could possibly be due to reduced drive from nerve cells in the brain (cortical neurons) or to the effect of alterations in the number of surviving peripheral nerve axons and an increase in the number of muscle fibres they innervate (<a href="./references#CD008146-bbs2-0044" title="Martinez‐FigueroaA , HansenS , BallantyneJP . A quantitative electrophysiological study of acute idiopathic polyneuritis. Journal of Neurology, Neurosurgery and Psychiatry1977;40(2):156‐61. ">Martinez‐Figuerora 1977</a>; <a href="./references#CD008146-bbs2-0054" title="SandersDB , StalbergEV , NandedkarSD . Analysis of the electromyographic interference pattern. Journal of Clinical Neurophysiology1996;13(5):385‐400. ">Sanders 1996</a>). In addition, psychological factors such as lack of motivation or low mood can also affect voluntary activation of muscles (<a href="./references#CD008146-bbs2-0026" title="GandeviaSC . Spinal and supraspinal factors in human muscle fatigue. Physiological Reviews2001;81(4):1725‐89. ">Gandevia 2001</a>; <a href="./references#CD008146-bbs2-0038" title="Kent‐BraunJA , SharmaKR , WeinerMW , MassieB , MillerRG . Central basis of muscle fatigue in chronic fatigue syndrome. Neurology1993;43(1):125‐31. ">Kent‐Braun 1993</a>). Fear of precipitating fatigue may also contribute and lead to an avoidance of physical activity and physical deconditioning, thus further exacerbating fatigue (<a href="./references#CD008146-bbs2-0048" title="Moss‐MorrisR , SharonC , TobinR , BaldiJC . A randomized controlled graded exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change. Journal of Health Psychology2005;10(2):245‐9. ">Moss‐Morris 2005</a>). Environmental factors may also precipitate fatigue, since many people with peripheral neuropathies have to utilise compensatory strategies such as orthoses or walking aids as a result of deformities or sensory deficits. Therefore, the experience of fatigue may be clearly related to known underlying factors or, more commonly, be only partly explained by these. Finally, measurement of the level of fatigue is difficult both because the subjective experience of fatigue varies between individuals and because measures of different types of fatigue are numerous. </p> </section> <section id="CD008146-sec-0032"> <h3 class="title" id="CD008146-sec-0032">Description of the intervention</h3> <p>The evidence about the efficacy of interventions for fatigue in peripheral neuropathy and other chronic conditions is limited and unclear. Interventions aim to address physical, environmental and psychological factors contributing to fatigue, and include drugs, pacing and grading of physical activity, general or specific exercise, orthotics, relaxation, counselling, cognitive behavioural strategies and others. </p> </section> <section id="CD008146-sec-0033"> <h3 class="title" id="CD008146-sec-0033">How the intervention might work</h3> <p>The presumed mode of action of drug interventions such as amantadine for generalised fatigue is unknown (<a href="./references#CD008146-bbs2-0052" title="PucciE , BrañasP , D'AmicoR , GiulianiG , SolariA , TausC . Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD002818.pub2] ">Pucci 2009</a>); one randomised controlled trial (RCT) showed no effect in inflammatory peripheral neuropathy (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>). It is likely that factors contributing to subjective fatigue in individuals with peripheral neuropathy must be clearly understood in order to target interventions effectively. For example, where fatigue is due to weakness, strengthening exercise may be beneficial, but where altered mood or well‐being is a factor then drug, cognitive or behavioural interventions may be more relevant. It is likely that multidimensional interventions that address individuals' self perception and health beliefs combined with strategies to increase levels of physical activity or participation in regular exercise or both may also be helpful. </p> </section> <section id="CD008146-sec-0034"> <h3 class="title" id="CD008146-sec-0034">Why it is important to do this review</h3> <p>Fatigue is a frequent and often severe problem that affects everyday activities and quality of life for people with peripheral neuropathy. Although there have been some RCTs of drug and non‐drug interventions for fatigue in peripheral neuropathy, we know of no systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008146-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008146-sec-0035"></div> <p>To assess the effects of drugs and physical, psychological or behavioural interventions for fatigue in adults or children with peripheral neuropathy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008146-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008146-sec-0036"></div> <section id="CD008146-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008146-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) or quasi‐RCTs of any drug or non‐drug intervention to treat fatigue associated with peripheral neuropathy, compared with placebo, no treatment or other drug or non‐drug interventions for fatigue. Quasi‐RCTs are those in which randomisation was intended but they use methodology that may be biased, such as alternation, or use of case record numbers or date of birth. </p> </section> <section id="CD008146-sec-0039"> <h4 class="title">Types of participants</h4> <p>We considered for inclusion in the review all trials in which participants (adults or children) had fatigue associated with a diagnosis of peripheral polyneuropathy, including sensory, motor and combined sensory and motor neuropathies. We did not consider trials including mostly people with focal disease such as local entrapment neuropathies with pain as the primary presenting feature (for example, cervical radiculopathy, carpal tunnel syndrome, brachial plexus neuritis, etc), and poliomyelitis. We accepted the diagnosis of peripheral neuropathy offered by the study authors, provided that it stipulated the presence of clinical impairment characteristic of peripheral neuropathy. We did not include diagnoses dependent on symptoms suggestive of neuropathy alone or neurophysiological abnormalities in the absence of clinical signs. </p> </section> <section id="CD008146-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We considered trials including any form of intervention for fatigue management, such as drugs, pacing and grading of physical activity, general or specific exercise, compensatory strategies such as orthotics, relaxation, counselling, cognitive and educational strategies and others, compared with either placebo, no intervention or an alternative form of intervention for fatigue. </p> </section> <section id="CD008146-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD008146-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Our primary outcome was fatigue severity and symptoms as measured by any validated scale evaluated at least four weeks and less than 12 weeks after commencement of the intervention. Where studies used more than one scale, we used the preferred ranking of commonly‐used scales shown below to identify the scale to be used in the primary outcome analysis. Instruments that we considered appropriate included: Fatigue Severity Scale (FSS) (<a href="./references#CD008146-bbs2-0040" title="KruppLB , LaRoccaNG , Muir‐NashJ , SteinbergAD . The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology1989;46(10):1121‐3. ">Krupp 1989</a>), Chalder Fatigue Scale (<a href="./references#CD008146-bbs2-0018" title="ChalderT , BerelowitzG , PawlikowskaT , WattsL , WesselyS , WrightD , et al. Development of a fatigue scale. Journal of Psychosomatic Research1993;37(2):147‐53. ">Chalder 1993</a>), Fatigue Impact Scale or daily‐FIS (D‐FIS) (<a href="./references#CD008146-bbs2-0024" title="FiskJD , RitvoPG , RossL , HaaseDA , MarrieTJ , SchlechWF . Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clinical Infectious Diseases1994;18(Suppl 1):S79‐83. ">Fisk 1994</a>; <a href="./references#CD008146-bbs2-0025" title="FiskJD , DobleSE . Construction and validation of a fatigue impact scale for daily administration (D‐FIS). Quality of Life Research2002;11(3):263‐72. ">Fisk 2002</a>), Visual Analogue Scale of Fatigue (VAS‐F) (<a href="./references#CD008146-bbs2-0042" title="LeeKA , HicksG , Nino‐MurciaG . Validity and reliability of a scale to assess fatigue. Psychiatry Research1991;36(3):291‐8. ">Lee 1991</a>), and Piper Fatigue Scale (PFS) (<a href="./references#CD008146-bbs2-0050" title="PiperBF , DibbleSL , DoddMJ , WeissMC , SlaughterRE , PaulSM . The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncology Nursing Forum1998;25(4):677‐84. ">Piper 1998</a>). </p> </section> <section id="CD008146-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p>1. Fatigue after 12 or more weeks.</p> <p>2. Activity limitations after 12 or more weeks.</p> <p>3. Participation restrictions after 12 or more weeks.</p> <p>4. Health‐related quality of life after 12 or more weeks.</p> <p>5. Adverse events: any adverse events, adverse events which lead to discontinuation of treatment and serious adverse events, which are those which are fatal, life‐threatening, or require prolonged hospitalisation. </p> </section> </section> </section> <section id="CD008146-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008146-sec-0045"> <h4 class="title">Electronic searches</h4> <p>On 5 November 2013, we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 10), MEDLINE (January 1966 to October 2013), EMBASE (January 1980 to October 2013), LILACS (January 1982 to October 2013), CINAHL Plus (January 1937 to October 2013) and AMED (January 1985 to October 2013). The detailed search strategies are in the appendices: <a href="./appendices#CD008146-sec-0099">Appendix 1</a> (MEDLINE), <a href="./appendices#CD008146-sec-0100">Appendix 2</a> (EMBASE), <a href="./appendices#CD008146-sec-0101">Appendix 3</a> (CINAHL Plus), <a href="./appendices#CD008146-sec-0102">Appendix 4</a> (CENTRAL), <a href="./appendices#CD008146-sec-0103">Appendix 5</a> (AMED), <a href="./appendices#CD008146-sec-0104">Appendix 6</a> (LILACS) and <a href="./appendices#CD008146-sec-0105">Appendix 7</a> (the Cochrane Neuromuscular Disease Group Specialized Register). </p> <p>On 12 June 2014 we searched the Current Controlled Trials register (<a href="http://www.controlled-trials.com/" target="_blank">www.controlled‐trials.com</a>), ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), using the search terms 'fatigue' and 'peripheral neuropathy'. </p> </section> <section id="CD008146-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of the randomised trials identified, contacted the trial authors and known experts in the field, and approached pharmaceutical companies to identify additional published or unpublished data. </p> </section> </section> <section id="CD008146-sec-0047"> <h3 class="title" id="CD008146-sec-0047">Data collection and analysis</h3> <section id="CD008146-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CMW, RCS) independently examined the titles and abstracts identified by the search. There were no language restrictions. We obtained English language translations where appropriate. We retrieved all trials that were relevant and reviewed full‐text publications. We examined retrieved publications against the selection criteria and we resolved any disagreement by consensus.We did not have to resort to arbitration by a third author (MPG). If trials had had a heterogenous sample of disorders, we would have only included them if data from participants with peripheral neuropathy could be isolated or if at least 75% of the participants had peripheral neuropathy. </p> </section> <section id="CD008146-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>For each retrieved publication, two review authors (CW and RCS) independently extracted the relevant data using standardised forms. We resolved any disagreements by discussion. We gathered data on: </p> <p> <ul id="CD008146-list-0001"> <li> <p>eligibility criteria;</p> </li> <li> <p>interventions;</p> </li> <li> <p>details of participants;</p> </li> <li> <p>assignment to groups;</p> </li> <li> <p>outcome measures;</p> </li> <li> <p>time at which outcomes are measured;</p> </li> <li> <p>funding;</p> </li> <li> <p>declarations of interest;</p> </li> <li> <p>sample size; and</p> </li> <li> <p>statistical analysis.</p> </li> </ul> </p> </section> <section id="CD008146-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two out of three review authors (CW, RS and MG) independently assessed all included studies for risk of bias. We graded the items according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008146-bbs2-0034" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>) and presented our assessments in a 'Risk of bias' table. We assessed trials for random sequence generation, allocation concealment, blinding (participants, personnel and outcome assessors), incomplete outcome data, selective outcome reporting and other potential sources of bias.<br/> <br/> We then made a judgement on each of these criteria relating to the risk of bias, of 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'. </p> </section> <section id="CD008146-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008146-sec-0052"> <h5 class="title">Continuous data</h5> <p>For studies using the same outcome measures, we summarised continuous data using mean differences (MDs), sometimes called 'weighted mean differences', with a corresponding 95% confidence interval (CI). When different studies measured the same outcome in different ways we analysed results using standardised mean differences (SMDs) with a 95% CI. </p> </section> <section id="CD008146-sec-0053"> <h5 class="title">Dichotomous data</h5> <p>For studies using similar outcomes with dichotomous data we calculated a pooled estimate of the risk ratio (RR), with a 95% CI. </p> </section> </section> <section id="CD008146-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>Where there were multiple intervention groups within a trial, we made pairwise comparisons of similar interventions or active components versus no treatment, placebo, or another intervention. We planned to analyse cross‐over trials with continuous outcome measures using generalised inverse variance analysis (GIV) (<a href="./references#CD008146-bbs2-0021" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>), where the estimated difference in the mean treatment effects and their standard errors were available for pooling with equivalent results from parallel‐group studies. If this information had not been available then we would have pooled data from the first phase only, where possible, with parallel design studies. For cross‐over studies with dichotomous outcomes we would have pooled results using odds ratios (ORs) and confidence intervals from paired analyses where available (<a href="./references#CD008146-bbs2-0023" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues.. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). Only one cross‐over trial was included for any comparison, so no decisions about pooling data were necessary. We would have reported trials with unique designs or outcomes without a meta‐analysis. We excluded studies that were not RCTs from the analyses but we comment on them in the <a href="#CD008146-sec-0083">Discussion</a>. </p> </section> <section id="CD008146-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>For all outcomes, where continuous data were presented as mean change with 95% CIs, the standard deviations (SDs) were calculated for input into analyses and forest plots assuming a normal distribution due to a moderate sample size, using the equation SD = SQRT of number of participants X (upper limit of CI to lower limit of CI) / 3.92. as recommended in Section 7.7.3.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008146-bbs2-0035" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). Where overall disability sum score (ODSS) data were presented as median and interquartile ranges, we did not input any data for analysis. Where participant dropout led to missing data we contacted trial authors if an intention‐to‐treat analysis had not been performed. We also contacted authors where there were missing data for review outcomes, and additional data were provided for the secondary outcome of participation in one study (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>). </p> </section> <section id="CD008146-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We undertook meta‐analysis when studies investigated similar interventions, used similar outcome measures and included groups of participants who were clinically homogeneous. Where studies were heterogeneous for some outcomes we undertook a narrative review. </p> <p>If studies were similar in intervention, outcome measurement and participants, we assessed possible inconsistency across studies using the I² statistic (<a href="./references#CD008146-bbs2-0033" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>; <a href="./references#CD008146-bbs2-0034" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). If studies had been heterogeneous (Q statistic = 0.1 and I² statistic of 25% or greater), the review authors would have considered conducting subgroup analysis only. If we had considered the primary studies to be heterogeneous even within subgroups, we would have undertaken a narrative approach rather than a meta‐analysis. </p> </section> <section id="CD008146-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not use funnel plots to investigate associations between effect size and study precision in terms of sample size, because of the small number of studies included in the review. If we had included funnel plots, we would have explored the relationships observed to investigate differences between studies with large and small samples, or systematic biases, such as publication bias. </p> </section> <section id="CD008146-sec-0058"> <h4 class="title">Data synthesis</h4> <p>For studies with a similar type of intervention or a similar active component, we performed a meta‐analysis to calculate a treatment effect across trials with a fixed‐effect model, as heterogeneity was not demonstrated. Dichotomous outcome results were available from only one study so we did not present pooled RRs. Where it was not possible to perform a meta‐analysis we provided descriptive summaries of the results from each trial. </p> <section id="CD008146-sec-0059"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables using the following outcomes:</p> <p> <ol id="CD008146-list-0002"> <li> <p>Fatigue severity and symptoms between four and 12 weeks after commencement of the intervention. </p> </li> <li> <p>Fatigue after 12 or more weeks.</p> </li> <li> <p>Activity limitations after 12 or more weeks.</p> </li> <li> <p>Participation restrictions after 12 or more weeks.</p> </li> <li> <p>Health‐related quality of life after 12 or more weeks.</p> </li> <li> <p>Serious adverse events.</p> </li> </ol> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence (studies that contribute data) for the prespecified outcomes. We used methods and recommendations described in Chapters 11 and 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008146-bbs2-0056" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>; <a href="./references#CD008146-bbs2-0057" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions.. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We used GRADEpro software (<a href="./references#CD008146-bbs2-0029" title="Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008. ">GRADEpro 2008</a>). We explained decisions to down‐ or up‐grade the quality of studies using footnotes and we made comments to aid reader's understanding of the review where necessary. </p> </section> </section> <section id="CD008146-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Insufficient data available. See <a href="./appendices#CD008146-sec-0106">Appendix 8</a> for methods planned but not implemented. </p> </section> <section id="CD008146-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>Insufficient data available. See <a href="./appendices#CD008146-sec-0106">Appendix 8</a> for methods planned but not implemented. </p> <p>This review has a protocol (<a href="./references#CD008146-bbs2-0061" title="WhiteCM , vanDoornPA , GarssenMPJ , StockleyRC . Interventions for fatigue in peripheral neuropathy. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD008146] ">White 2009</a>). We listed any deviations from the protocol in <a href="#CD008146-sec-0115">Differences between protocol and review</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008146-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008146-sec-0062"></div> <section id="CD008146-sec-0063"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD008146-sec-0117" title="">Characteristics of included studies</a> and <a href="./references#CD008146-sec-0118" title="">Characteristics of excluded studies</a> for details. </p> <p>The electronic and manual searches identified a total of 1386 titles and abstracts. After removing duplicates and excluding abstracts where studies were clearly not eligible for inclusion, only six full publications, four protocols and two abstracts were relevant to the review. After reading the full text of the six published articles we excluded three: two were not randomised controlled trials (RCTs) (<a href="./references#CD008146-bbs2-0005" title="CarterGT , HanJJ , MayadevA , WeissMD . Modafinil reduces fatigue in Charcot‐Marie‐Tooth disease type 1A: a case series. American Journal of Hospice and Palliative Care2006;23(5):412‐6. ">Carter 2006</a>; <a href="./references#CD008146-bbs2-0006" title="EnderlinCA . Peripheral neuropathy, sleep and fatigue related to cancer and chemotherapy: preliminary findings. Southern Online Journal of Nursing Research2008;8(2):2p. ">Enderlin 2008</a>) and one was an RCT of ascorbic acid for children with CMT1A in which fatigue was not an outcome (<a href="./references#CD008146-bbs2-0004" title="BurnsJ , OuvrierRA , YiuEM , JosephPD , KornbergAJ , FaheyMC , et al. Ascorbic acid for Charcot‐Marie‐Tooth disease type 1A in children: a randomised, double‐blind, placebo‐controlled safety and efficacy trial. Lancet Neurology2009;8(6):537‐44. ">Burns 2009</a>). We included one abstract of conference proceedings, regarding an RCT of a new low‐dose combination of three already approved drugs for CMT1A, as an ongoing trial, as the analyses are ongoing (<a href="./references#CD008146-bbs2-0009" title="AttarianS , DubourgO , FunalotB , GonnaudP‐M , LacourA , MagyL , et al. A phase II randomized, placebo‐controlled multicenter clinical trial of three doses of PXT3003 in 80 adult patients with CMT1A treated for 1 year. Journal of the Peripheral Nervous System2013;18(s2):S7‐S8. ">Attarian 2013</a>). We will include this study in future updates of this review if appropriate. Two of the other five ongoing or unpublished studies were RCTs of ascorbic acid in CMT1, and we contacted the authors for further information (<a href="./references#CD008146-bbs2-0007" title='NCT00484510 . A randomized, placebo‐controlled, double masked 120 subject "futility design" clinical trial of ascorbic acid treatment of Charcot Marie Tooth disease type 1A. clinicaltrials.gov/ct2/show/NCT00484510 (accessed 21 January 2013). '>NCT00484510</a>; <a href="./references#CD008146-bbs2-0008" title="VerhammeC , deHaanRJ , VermeulenM , BaasF , deVisserM , vanSchaikIN . Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double‐blind, placebo‐controlled phase 11 trial. BMC Medicine2009;7(1):70‐79. ">Verhamme 2009</a>). However, in these ongoing studies, fatigue was not included as an outcome and we excluded them. One randomised trial of coenzyme Q10 for CMT (<a href="./references#CD008146-bbs2-0010" title="NCT00541164 . Effects of coenzyme Q10 on Charcot‐Marie‐Tooth disease. //clinicaltrials.gov/ct2/show/NCT00541164 (accessed 12 June 2014). ">NCT00541164</a>), with changes in weakness, fatigue and pain as the primary outcome, is completed but appears to be unpublished. <a href="./references#CD008146-bbs2-0011" title="NCT02121678 . Effect of resistance and aerobic exercise in CIDP or MMN. www.clinicaltrials.gov/ct2/show/NCT02121678 (accessed 12 June 2014). ">NCT02121678</a> is not yet recruiting, but will study resistance training for chronic inflammatory demyelinating neuropathy (CIDP) with the fatigue severity scale (FSS) as a planned secondary outcome. We identified one study, <a href="./references#CD008146-bbs2-0012" title="RamdharryGM , PollardAJ , AndersonCA , LauráM , MurphySM , HuttonEJ , et al. Strengthening hip flexors to improve walking distance in people with Charcot‐Marie‐Tooth disease. Journal of the Peripheral Nervous System. 2011; Vol. 16 (Suppl 3):S115‐6. ">Ramdharry 2011</a>, from an abstract in the Cochrane Neuromuscular Disease Group Specialized Register. The study appears to be ongoing and the authors provided no data when contacted. We will include it if eligible once the full publication is available. See <a href="./references#CD008146-sec-0119" title="">Characteristics of ongoing studies</a>. </p> <p>The study selection process therefore resulted in only three trials finally meeting the criteria for inclusion (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>; <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>). </p> <section id="CD008146-sec-0064"> <h4 class="title">Study design and participants</h4> <p>We include three studies evaluating the efficacy of two drugs for fatigue in two different populations (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>; <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>). </p> <p>The first study (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>) was a randomised, double‐blind, placebo‐controlled, cross‐over trial of amantadine for severe fatigue in 80 neurologically well‐recovered participants who had had Guillain‐Barré syndrome (GBS). Randomisation was in blocks of six with half the study participants receiving amantadine first and the remainder receiving placebo first. Interventions were followed by a two‐week washout period. Assessment of outcomes occurred on six occasions: 1: at baseline, 2: following two weeks of no intervention, 3: after six weeks of intervention 1, 4: after a two‐week washout period, 5: after six weeks of intervention 2, and finally 6: after a further two‐week washout period. Three randomised participants were withdrawn from the study in the pre‐cross‐over phase. One participant was in the placebo group and withdrew because of concern over potential side effects of amantadine when she became pregnant. The two other participants were in the amantadine treatment group; one withdrew because of hospital admission with acute cholangitis and the second participant developed severe complaints of dizziness. A further three participants were excluded from the analysis due to incorrect completion of the FSS. Therefore, 74 participants with GBS were included in the reporting of outcomes. All participants had been diagnosed with GBS between six months and 15 years previously and had no apparent changes in GBS disability score for the three months prior to entering the study. All could walk at least 10 metres with or without a walking aid (GBS disability score &lt; 3). </p> <p>The two remaining studies (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) were parallel‐group, randomised, double‐blind, placebo‐controlled trials of the effect of ascorbic acid in a total of 450 adults with Charcot‐Marie‐Tooth disease type 1A (CMT1A). In one, two doses (either 1 g or 3 g daily) of ascorbic acid or placebo were used in the treatment of 179 participants (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>). Confirmation of diagnosis was by clinical examination and genotyping with duplication in 17p11.2 and at least one motor sign or symptom (gait disorder, distal amyotrophy, foot deformation or distal weakness). Block randomisation into three groups with matching for study site and sex was followed by 12 months of treatment with either 1 g or 3 g of ascorbic acid or placebo; outcomes were assessed at baseline and after 12 months of intervention. A total of 16 participants withdrew from the study after randomisation due to adverse events (six), withdrawal of consent (six), loss to follow‐up (two), non‐compliance (one) or missing baseline data (one). </p> <p>Therefore, 163 participants completed the study but analysis was of all 179 participants, on an intention‐to‐treat basis. </p> <p>In the second multicentre study (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>), the efficacy of chronic administration, for 24 months, of either 1.5 g/day ascorbic acid or placebo in the treatment of 271 participants (eligible for analysis) with Charcot‐Marie‐Tooth disease 1A was evaluated. Participants had a clinical diagnosis of Charcot‐Marie‐Tooth disease 1A with genetic confirmation of 17p11.2‐p12 duplication and a CMT neuropathy score of between 1 (excluding the electrophysiological component) and 35 (including the electrophysiological component). Block randomisation of 277 participants into groups of four stratified by disease severity and centre was followed by 24 months of treatment with either ascorbic acid or placebo, and outcomes were assessed at six‐monthly intervals from commencement of intervention until 24 months. Six participants did not receive the allocated intervention after randomisation, and are dropped from the denominators. A total of 22 participants withdrew from the intervention after commencement. Reasons for withdrawal were adverse events (13), withdrawal of consent (six), moved away from study area (two) or for personal reasons (one). Whilst the primary study outcome was based on all randomised patients who received at least one dose of the study drug using imputation for missing data the secondary analyses were conducted without imputation of missing data. </p> </section> <section id="CD008146-sec-0065"> <h4 class="title">Interventions</h4> <p>The study of amantadine in Guillain‐Barré syndrome was a cross‐over trial in which amantadine was compared with placebo at a dose of one tablet (100 mg) daily for one week followed by two tablets daily for the remaining five weeks of each intervention period. A washout period of two weeks was incorporated before the participants shifted to the other treatment arm (amantadine or placebo) (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>). </p> <p>The studies of ascorbic acid in Charcot‐Marie‐Tooth disease 1A were a parallel‐group study comparing 1 g or 3 g of ascorbic acid in a single administration of three capsules with three placebo capsules for 12 months (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>) and a parallel‐group study comparing 1.5 g of ascorbic acid in two daily doses with placebo tablets for 24 months (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>). </p> </section> <section id="CD008146-sec-0066"> <h4 class="title">Outcomes</h4> <p>In participants with severe fatigue due to Guillain‐Barré syndrome (defined as Fatigue Severity Scale (FSS) 5.0 or more; FSS range 1 to 7), <a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> used a reduction of at least one point on the FSS as a primary outcome measure of fatigue. Outcomes for FSS were reported for both phases of the cross‐over study. Secondary outcome measures in the major domains of the International Classification of Functioning, Disability and Health (ICF) were: for structure and function, anxiety and depression using the Hospital Anxiety and Depression Scale (HADS); for activity, impact of fatigue using the Fatigue Impact Scale (FIS); and for participation, Rotterdam Handicap Scale (RHS), quality of life using the Medical Outcomes Short Form‐36 (SF‐36) Health Survey and the Euroquol Health Questionnaire (EQHQ); and adverse events. </p> <p>In the studies of ascorbic acid in participants with Charcot‐Marie‐Tooth disease 1A, the primary outcome was CMT neuropathy score (CMTNS). Fatigue was assessed as a secondary outcome using the change in Visual Analogue Scale ‐ Fatigue (VAS‐F), either 12 months (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>) or 24 months (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) after commencement of the intervention. Secondary outcomes of activity limitation using the Overall Disability Sum Score (ODSS) (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>) or Overall Neuropathy Limitations Scale (ONLS) (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>), 10 metre walk test (10MWT) <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a> and 9 hole peg test (9HPT) (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) were reported, as well as measures of participation and quality of life using the SF‐36 and adverse events in both studies. </p> </section> </section> <section id="CD008146-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD008146-sec-0117" title="">Characteristics of included studies</a> for details and <a href="#CD008146-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008146-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias." data-id="CD008146-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias. </p> </div> </div> </div> <p><a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> conducted block randomisation in blocks of six, although allocation was concealed from researchers; we therefore considered the study to be at low risk of bias for these criteria. The trial was a double‐blind, placebo‐controlled study, with 80 participants initially enrolled. Although the final analysis was based on 74 participants as six were withdrawn, there was adequate reporting of the loss to follow‐up. Sample size was calculated using estimates of proportion from unpublished data obtained from a pilot study, indicating that 36 participants per group were required for 90% power at a two‐sided 5% alpha, so that with 77 participants completing the trial it was sufficiently powered to detect a difference. The washout period of two weeks between cross‐over intervention phases seems sufficient to avoid a carry‐over effect of amantadine, and is comparable with other randomised controlled cross‐over designs of efficacy for amantadine in other populations (<a href="./references#CD008146-bbs2-0019" title="CohenRA , FisherM . Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology1989;46(6):676‐80. ">Cohen 1989</a>; <a href="./references#CD008146-bbs2-0052" title="PucciE , BrañasP , D'AmicoR , GiulianiG , SolariA , TausC . Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD002818.pub2] ">Pucci 2009</a>; <a href="./references#CD008146-bbs2-0053" title="RosenbergGA , AppenzellerO . Amantadine, fatigue, and multiple sclerosis. Archives of Neurology1988;45(10):1104‐6. ">Rosenberg 1988</a>). The authors reported data for mean (SD) improvement in FSS scores for both amantadine and placebo treatment in both the amantadine‐placebo (0.46 (1.29), P = 0.078; 95% CI ‐0.92 to 0.05) and placebo‐amantadine sequence (0.08 (1.44), P = 0.28; 95% CI ‐1.24 to 0.44) groups and t‐test analysis for period effects and carry‐over effects were not significant. There was some evidence of selective reporting of secondary outcomes, as only P values were reported. Overall we considered the study to be at low risk of bias. </p> <p>In <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>, sequence generation was conducted by an independent contract research organisation who were also responsible for concealed allocation of randomisation into blocks of 12 that were stratified for sex and study site (three sites). The trial was double‐blind with the administration of visually identical hard gelatin capsules for all groups. Analysis was on an intention‐to‐treat basis with 179 participants randomised and analysed despite 15 withdrawals prior to follow‐up (four from the placebo group, eight from the 1 g ascorbic acid group and three from the 3 g ascorbic acid group); one participant from the placebo group had missing baseline data for the study's primary outcome. All study outcomes were adequately reported. Whilst authors stated that the data were analysed on an intention‐to‐treat basis there was no indication of how the investigators dealt with the missing data from 16 participants. Our overall summary assessment was that the study was at low risk of bias. </p> <p>In the third study (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>), an independent randomisation unit was responsible for sequence generation and group allocation stratified for disease severity and treatment centre in blocks of four. This, combined with the use of placebo tablets of identical appearance, taste and smell, resulted in blinding of participants, researchers and treating physicians. Six participants randomised to the intervention (four participants) and placebo (two participants) groups withdrew consent before receiving the allocated intervention and were excluded from analysis. Although the investigators recorded outcome data at six‐monthly intervals for 24 months, the authors stated that their main analysis would be at 24 months, and reported the primary outcome at only 12 and 24 months and the secondary outcomes only at 24 months. Overall we considered this study to be at low risk of bias.     </p> </section> <section id="CD008146-sec-0068"> <h3 class="title" id="CD008146-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD008146-tbl-0001"><b>Summary of findings for the main comparison</b> Amantadine versus placebo for fatigue in Guillain‐Barré syndrome</a>; <a href="./full#CD008146-tbl-0002"><b>Summary of findings 2</b> Ascorbic acid versus placebo for fatigue in peripheral neuropathy</a> </p> <section id="CD008146-sec-0069"> <h4 class="title">Amantadine versus placebo in Guillain‐Barré syndrome</h4> <p>Effect estimates, where data were available, were obtained from a single trial, so we downgraded the quality of evidence for all outcomes for this reason (<a href="./full#CD008146-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD008146-sec-0070"> <h5 class="title">Primary outcome</h5> <section id="CD008146-sec-0071"> <h6 class="title">Fatigue between four and 12 weeks after commencement of intervention</h6> <p><a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> assessed baseline measures at visit 1 and at visit 2, prior to randomisation. In the 74 participants for whom full outcome data were reported, there was evidence of a reduction in fatigue between these baseline visits, which was stated by the authors to approach significance (P = 0.05 Wilcoxon signed rank test), although complete group data were not presented. The magnitude of fatigue reduction before the start of any intervention was such that although the median FSS score for the 74 participants was 5.9 at visit 2, seven (9%) of the participants had an FSS score lower than the inclusion criterion of FSS 5 for severe fatigue. </p> <p>Thirty‐six participants received amantadine followed by placebo and 38 received placebo followed by amantadine. Favourable outcome reporting was available for both phases of each treatment sequence, representing evaluation of the primary outcome six weeks after the commencement of intervention. Results were presented as the mean difference (MD) in reduction in FSS scores between amantadine and placebo, and as an odds ratio (OR) of a favourable outcome (defined as a reduction of more than 1 in FSS score). The overall MD in FSS score between amantadine and placebo phases was ‐0.45 (95% CI ‐0.94 to 0.04; <i>t</i> = ‐1.80; df = 73; P = 0.076). When the participants responding favourably to one treatment only in both the group receiving amantadine followed by placebo (amantadine‐placebo group) and those receiving placebo followed by amantadine (placebo‐amantadine group) were combined, the number with a more favourable outcome following amantadine was 9 of 25 (36%) participants with an OR of 0.56 (95% CI 0.22 to 1.35, P = 0.16) using the McNemar test. </p> </section> </section> <section id="CD008146-sec-0072"> <h5 class="title">Secondary outcomes</h5> <p>All stated secondary outcomes in <a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> were only reported at six weeks after commencement of the intervention and therefore not at the stated secondary outcome point of 12 or more weeks after commencement of intervention for this review. In addition full data for the study secondary outcomes were not available, as only P values were provided (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>). The data indicated that there was no significant improvement in: fatigue impact using the fatigue impact scale (FIS) (P = 0.77); participation using the Rotterdam Handicap Scale (RHS) (P = 0.14) and Euroquol Health Questionnaire (EQHQ) (P = 0.21) at six weeks. The authors reported that quality of life using the SF‐36 demonstrated a significant improvement in physical role functioning (P = 0.008) and mental health perception (P = 0.008), although only in the placebo group (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>). We contacted the authors for further information about secondary outcomes; the RHS scores for participation at six weeks from the original data were provided by the trial author (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>). The data were analysed using a paired two‐sample t‐test and showed that the MD between the change in participation with placebo versus the change with amantadine between four to 12 weeks after commencement of intervention was 0.31 (95% CI ‐0.09 to 0.72, P = 0.13) (<a href="#CD008146-tbl-0003">Table 1</a>). (<a href="./full#CD008146-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="table" id="CD008146-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data and analysis: amantadine versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect estimate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in participation (using the Rotterdam Handicap Scale) &gt; 12 weeks after commencement of intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (cross‐over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 [‐0.09 to 0.72]</p> </td> </tr> </tbody> </table> </div> <p><b>Fatigue after 12 or more weeks</b> </p> <p>Not reported at this time point.</p> <p><b>Activity limitations after 12 or more weeks</b> </p> <p>Not reported at this time point.</p> <p><b>Participation restrictions after 12 or more weeks</b> </p> <p>Not reported at this time point.</p> <p><b>Health‐related quality of life (HRQoL) after 12 or more weeks</b> </p> <p>Not reported at this time point.</p> <section id="CD008146-sec-0073"> <h6 class="title">Adverse events</h6> <p>Reported in <a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>. </p> <p>No serious adverse events were reported. However, mild, transient adverse effects were reported in 32 out of 80 (40%) participants: 22 participants during amantadine treatment and 10 during placebo treatment. Adverse effects included anticholinergic complaints (six participants: three in each treatment group), gastrointestinal complaints (10 participants: seven in placebo group and three in amantadine group), sleep complaints (10 participants: nine in amantadine group and one in placebo group) and other less frequent side effects (headache, feelings of nervousness and vivid dreams). No side effects were reported to have affected trial participation. </p> </section> </section> </section> <section id="CD008146-sec-0074"> <h4 class="title">Ascorbic acid versus placebo in Charcot‐Marie‐Tooth disease</h4> <section id="CD008146-sec-0075"> <h5 class="title">Primary outcome</h5> <section id="CD008146-sec-0076"> <h6 class="title">Fatigue between four and 12 weeks after commencement of intervention</h6> <p>Neither study evaluating ascorbic acid for Charcot‐Marie‐Tooth disease 1A reported change in fatigue within the time scale of the primary outcome for this review (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>). </p> </section> </section> <section id="CD008146-sec-0077"> <h5 class="title">Secondary outcomes</h5> <p>Data for secondary outcomes were reported at 12 months after commencement of the intervention in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and at 24 months after commencement of the intervention in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. Where two different doses of ascorbic acid were used in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>, we combined data from both intervention arms, including participants receiving a higher dose (3 g ascorbic acid) and those receiving a lower dose (1 g ascorbic acid) in comparisons for all outcomes. </p> <section id="CD008146-sec-0078"> <h6 class="title">Fatigue after more than 12 weeks</h6> <p>Reported in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. </p> <p>Both studies assessed fatigue using change in Visual Analogue Scale for fatigue (VAS‐F). Fatigue was assessed at 12‐month follow‐up using a 0 to 100 VAS for fatigue in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and at 24‐month follow‐up using a 0 to 10 VAS for fatigue in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. The pooled estimate of effect of the change in fatigue more than 12 weeks after commencement of the intervention was standardised mean difference (SMD) ‐0.12 (95% CI ‐0.32 to 0.08, P = 0.25; N = 404; I² = 0%) (see <a href="./references#CD008146-fig-0006" title="">Analysis 1.1</a>; <a href="#CD008146-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008146-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.1 Change in fatigue &gt; 12 weeks after commencement of intervention at 12 months [VAS 0 ‐ 100)." data-id="CD008146-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.1 Change in fatigue &gt; 12 weeks after commencement of intervention at 12 months [VAS 0 ‐ 100). </p> </div> </div> </div> </section> <section id="CD008146-sec-0079"> <h6 class="title">Activity limitations after 12 or more weeks</h6> <p>Reported in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. </p> <p>Activity limitation was assessed using the ODSS at 12 months after commencement of intervention in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and the Overall Neuropathy Limitations Scale (ONLS) 24 months after commencement of intervention in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. Pooling of data in a meta‐analysis was not possible since data for ordinal scale scores were presented as medians plus interquartile ranges (IQRs), and there was no indication of whether the data were skewed. However, the authors reported that there was no significant difference (P = 0.22) in median change in activity limitation between placebo and 1 g or 3 g doses of ascorbic acid at 12 months in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>, and no significant difference (P = 0.99) in median change in activity limitation between placebo and 1.5 g dose of ascorbic acid in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. </p> <p>In addition, further measures of activity limitation were included in both studies. The 10MWT was measured in both <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a> (at 12 months and 24 months, respectively) and the pooled estimate of effect for change in time taken to walk 10 metres more than 12 weeks after commencement of the intervention was MD ‐0.39 (95% CI ‐1.04 to 0.26, P = 0.24; N = 406; I² = 0%) (<a href="./references#CD008146-fig-0007" title="">Analysis 1.2</a>; <a href="#CD008146-fig-0003">Figure 3</a>). In addition the 9HPT was measured in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a> at 24 months and showed that there was no significant effect of ascorbic acid (MD ‐0.74, 95% CI ‐1.60 to 0.12, P = 0.09; N = 224) (<a href="./references#CD008146-fig-0008" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD008146-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Ascorbic acid versus placebo, outcome: 1.2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months) [seconds]." data-id="CD008146-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ascorbic acid versus placebo, outcome: 1.2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months) [seconds]. </p> </div> </div> </div> </section> <section id="CD008146-sec-0080"> <h6 class="title">Participation restrictions after 12 or more weeks</h6> <p>Not reported in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> or <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. </p> </section> <section id="CD008146-sec-0081"> <h6 class="title">Health‐related quality of life (HRQoL) after 12 or more weeks</h6> <p>Reported as an outcome and assessed using the SF‐36 at 12 months after commencement of the intervention in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and 24 months after commencement of the intervention in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. We calculated a pooled estimate of the change in physical functioning, as measured by the Physical Component Score (PCS) in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and the Physical Function Scale (PFS) of the SF‐36 in <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. Using data from 400 participants, the SMD was 0.08 (95% CI ‐0.12 to 0.28) favouring placebo (see <a href="#CD008146-fig-0004">Figure 4</a>, <a href="./references#CD008146-fig-0009" title="">Analysis 1.4</a>). There was no significant statistical heterogeneity, despite the difference in duration of follow‐up (I² = 0%, P = 0.67). </p> <div class="figure" id="CD008146-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.4 Change in physical function score of SF‐36." data-id="CD008146-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.4 Change in physical function score of SF‐36. </p> </div> </div> </div> <p><a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> reported HRQoL assessed by the Mental Component Score of the SF‐36 and for this too there was no significant difference (P = 0.77) between either dose of ascorbic acid versus placebo or in a combined analysis, between both doses of ascorbic acid versus placebo, 12 months after the start of treatment (<a href="./references#CD008146-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD008146-sec-0082"> <h6 class="title">Adverse events</h6> <p>Reported in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> and <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>. </p> <p>In <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>, 896 adverse events were documented in 158 (89%) participants (55 of 62 participants in the placebo group (89%); 47 of 56 participants in the 1 g ascorbic acid group (89%), and 56 of 61 participants in the 3 g ascorbic acid group (92%)), of which only 24 were serious adverse events. Serious adverse events were recorded in 22 participants (eight in the placebo group, seven in the 1 g ascorbic acid group and seven in the 3 g ascorbic acid group). Researchers deemed the majority of events (70%) not to be related to treatment and 208 (25%) to have a possible relation to treatment, of which only 12 (11 listed in the report) were severe: upper abdominal pain (2), dyspepsia (2), headache (1), insomnia (1), muscle spasm (1), musculoskeletal stiffness (1), rash (1), rhinitis (1) and sleep disturbance (1). Six participants (one in the placebo group, four in the 1 g ascorbic acid group and one in the 3 g ascorbic acid group) gave adverse events (cystitis, myalgia, depression, colitis and insomnia) as reasons for withdrawal from the study. </p> <p>In <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>, 21 serious adverse events were documented in 20 participants (eight events in seven of 138 participants in the ascorbic acid group and 13 events in 13 of 133 participants in the placebo group). Researchers considered all but one event, where a woman in the placebo group was admitted to hospital due to anaemia, as unrelated to the intervention. Thirteen participants experiencing adverse events were lost to follow‐up (six in the placebo group and seven in the ascorbic acid group), and eight participants (six in the placebo group and two in the ascorbic acid group) ceased treatment as a result of a serious adverse event. Five of these eight continued with follow‐up and three (two receiving placebo and one receiving ascorbic acid) withdrew from the study. Adverse events in those who discontinued the interventions included gastralgia, abdominal cramps or diarrhoea (9), surgery (4), renal colic (1), pregnancy (3), rectal bleeding (1), saccharine intolerance (1) and gum disease (1). The pooled risk ratio (RR) for serious adverse events in studies of ascorbic acid for CMT1A was 0.70 (95% CI 0.39 to 1.27, P = 0.24; N = 450; I² = 0%) (see <a href="./references#CD008146-fig-0011" title="">Analysis 1.6</a>, <a href="#CD008146-fig-0005">Figure 5</a>), indicating no significant difference in serious adverse events between ascorbic acid and placebo. </p> <div class="figure" id="CD008146-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.6 Adverse events." data-id="CD008146-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.6 Adverse events.</p> </div> </div> </div> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008146-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008146-sec-0083"></div> <section id="CD008146-sec-0084"> <h3 class="title" id="CD008146-sec-0084">Summary of main results</h3> <p>Our search identified three randomised controlled trials (RCTs) that met the inclusion criteria. The trials evaluated the effect of two different drugs on fatigue in two different populations of people with peripheral neuropathy. Two studies examined the effect of different doses of ascorbic acid in Charcot‐Marie‐Tooth disease 1A, and therefore no combined analysis was possible. </p> <p>The first study (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>) was a block‐randomised, double‐blind, placebo‐controlled, cross‐over study of amantadine for severe fatigue in 74 neurologically stable participants at least six months after Guillain‐Barré syndrome. We judged the risk of bias of the trial to be low. The study reported a moderate reduction in fatigue severity scale (FSS) score for participants treated with amantadine but the confidence interval was wide and study size relatively small, suggesting that the study may have been underpowered to detect a difference; we therefore graded the quality of the evidence as low. These data indicate that larger studies might improve the power to detect a reduction in risk of fatigue with amantadine. Nevertheless, the mean difference (MD) did not exceed the minimal clinically important difference for change in FSS scores estimated for people with systemic lupus erythematosus (MD 0.6; 95% CI 0.3 to 0.9), indicating that it is likely that there is no effect of amantadine compared with placebo in the treatment of severe fatigue (see <a href="./full#CD008146-tbl-0001">summary of findings Table for the main comparison</a>). A significant decrease in fatigue was noted between two pre‐treatment baseline visits two weeks apart. Since the participants were considered to be neurologically stable, this suggests that increased attention to people with fatigue due to Guillain‐Barré syndrome may improve symptoms of fatigue. </p> <p>The two studies evaluating ascorbic acid for Charcot‐Marie‐Tooth (CMT) disease 1A were block‐randomised, double‐blind, placebo‐controlled trials of different doses of ascorbic acid for the treatment of Charcot‐Marie‐Tooth disease 1A (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>). The risk of bias for <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> was low, despite the fact that there was no report of how missing data were dealt with in the intention‐to‐treat analysis. All other aspects of risk of bias assessment were adequate. The main findings were that whilst ascorbic acid was well‐tolerated and safe for adults with Charcot‐Marie‐Tooth disease 1A over a period of 12 months, there were no significant differences in effect across all outcomes, including fatigue, between placebo, 1 g or 3 g of ascorbic acid (see <a href="./full#CD008146-tbl-0002">summary of findings Table 2</a>). There was a low risk of bias in the remaining study (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>), and the main findings were that ascorbic acid supplementation at a dose of 1.5 g per day for 24 months was well tolerated but there was no significant effect on neuropathy or secondary outcomes compared with placebo. </p> </section> <section id="CD008146-sec-0085"> <h3 class="title" id="CD008146-sec-0085">Overall completeness and applicability of evidence</h3> <p>Only three RCTs (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>; <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) were eligible for inclusion in the review. One was of amantadine for severe fatigue in Guillain‐Barré syndrome and the others were of three different doses of ascorbic acid for people with Charcot‐Marie‐Tooth disease 1A. RCTs evaluating the effect of other interventions for fatigue, such as other drugs; pacing and grading of physical activity; general or specific exercise; compensatory strategies such as orthotics; relaxation; counselling; cognitive and educational strategies; and interventions for fatigue that form part of a multidimensional programme, or trials of interventions for other causes of peripheral neuropathy, were not available. None of the included studies considered the cost effectiveness of interventions for fatigue in peripheral neuropathy </p> </section> <section id="CD008146-sec-0086"> <h3 class="title" id="CD008146-sec-0086">Quality of the evidence</h3> <p>The overall risk of bias in the included trials (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>; <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) was low. </p> <p><a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> reported a double‐blind, placebo‐controlled study, where, despite a block randomisation procedure affecting bias in sequence generation and incomplete reporting of secondary outcomes, there was effective allocation concealment and P values for secondary outcomes were available. Reporting of data for fatigue during both phases of the trial indicates that there was no significant carry‐over effect. We therefore judged the overall risk of bias to be low. </p> <p><a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> reported a block‐randomised, double‐blind, placebo‐controlled study, where all assessed aspects of risk of bias were adequate except for the lack of reporting of how missing data were dealt with for an intention‐to‐treat analysis. We therefore judged the overall risk of bias to be low. </p> <p><a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a> reported a block‐randomised, double‐blind, placebo‐controlled study with a low risk of bias overall. </p> <p>Since only one trial of amantadine for the treatment of fatigue in Guillain‐Barré syndrome (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>) and two trials of ascorbic acid for treatment of Charcot‐Marie‐Tooth disease 1A (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) are included in the review, it is not possible to address the review objectives for drug or other interventions. The <a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> study was relatively small (74 participants) and the results actually suggest that there may be an effect, but the study is under‐powered. We downgraded the evidence from this study to low because of its imprecision (<a href="./full#CD008146-tbl-0001">summary of findings Table for the main comparison</a>). Larger studies including those with different doses and frequency of administration of amantadine are desirable before a definite conclusion about the effect of amantadine to treat fatigue in peripheral neuropathy and in particular in Guillain‐Barré syndrome can be given. </p> <p>The studies of ascorbic acid for Charcot‐Marie‐Tooth disease 1A were larger, and evaluated the effect of three different doses of ascorbic acid in Charcot‐Marie‐Tooth disease 1A (<a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>; <a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>). The lack of reporting of how missing data were dealt with in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> means that it is difficult to assess whether the risk of bias is likely to have favoured the control or ascorbic acid treatment groups in this study . Nevertheless, the low risk of bias associated with the final study (<a href="./references#CD008146-bbs2-0003" title="PareysonD , ReillyMM , SchenoneA , FabriziGM , CavallaroT , SantoroL , et al. Ascorbic acid in Charcot‐Marie‐Tooth disease type 1A (CMT‐TRIAAL and CMT‐TRAUK): a double‐blind randomised trial. Lancet Neurology2011;10(4):320‐8. [PUBMED: 21393063] ">Pareyson 2011</a>) and the fact that it has similar findings to <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a> meant that we did not downgrade the evidence because of trial design or conduct, but did downgrade it because of the lack of reporting of how missing data was dealt with in <a href="./references#CD008146-bbs2-0002" title="MicallefJ , AttarianS , DubourgO , GonnaudP‐M , HogrelJ‐Y , StojkovicT , et al. Effect of ascorbic acid in patients with Charcot‐Marie‐Tooth disease type 1A: a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2009;8(12):1103‐10. [PUBMED: 19818690] ">Micallef 2009</a>. This means that there is moderate‐quality evidence suggesting that ascorbic acid has no benefit in the treatment of fatigue in CMT (See <a href="./full#CD008146-tbl-0002">summary of findings Table 2</a>). </p> <p>The primary outcome of fatigue was evaluated using the FSS or VAS for fatigue in the included studies. The FSS is based on classical test theory (CTT), where scales may include items not relevant for particular clinical populations, and scale sum scores assume equal weighting of items where this has not necessarily been demonstrated. This potentially introduces bias into the assessment of the underlying outcome of interest. However, evidence in the current review was not downgraded due to directness based on outcomes used, since the effect of indirectness is not currently known. Nevertheless, clinicians and researchers are moving towards linearly weighted scales based on modern scientific methods such as Rasch models or item response theory (IRT) for evaluation of outcomes in clinical populations. The FSS has recently been fully evaluated and modified using the Rasch unidimensional measurement model (RUMM2020) and is recommended for use in immune‐mediated neuropathy (<a href="./references#CD008146-bbs2-0060" title="vanNesSI , VanhoutteEK , FaberCG , GarssenM , vanDoornPA , MerkiesIS , PeriNomS Study Group. Improving fatigue assessment in immune‐mediated neuropathies: the modified Rasch‐built Fatigue Severity Scale. Journal of the Peripheral Nervous System2009;14(4):268‐78. ">van Nes 2009</a>). Its relevance for other peripheral neuropathies remains to be evaluated. </p> </section> <section id="CD008146-sec-0087"> <h3 class="title" id="CD008146-sec-0087">Potential biases in the review process</h3> <p>Two review authors were also investigators in an included trial (<a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a>), but neither was involved in assessing the risk of bias in this study. </p> <p>We contacted study authors where there were missing data, and these was provided by <a href="./references#CD008146-bbs2-0001" title="GarssenMPJ , SchmitzPIM , MerkiesISJ , JacobsBC , van derMechéFGA , vanDoornPA . Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry2006;77(1):61‐5. [PUBMED: 16361594] ">Garssen 2006</a> for one secondary outcome. We also contacted authors of published abstracts with limited reporting of data for further information, but they either did not reply or declined to, stating their intention to publish a full report of the study in the future as a reason. </p> <p>This systematic review used an adequate search strategy to avoid missing any RCTs on treatments for fatigue in peripheral neuropathy. There were no language restrictions in our searches, and whilst a limitation of the review is that we did not initially plan in our protocol to search clinical trials registers, this additional search was subsequently conducted; this difference between the protocol and review is flagged up below. </p> <p>The criteria for types of participants for including studies accepted the diagnosis of peripheral neuropathy offered by the authors, provided that it stipulated the presence of clinical impairment characteristic of peripheral neuropathy. We considered only sensory, motor or combined sensory and motor peripheral neuropathies, and excluded studies of participants with focal entrapment neuropathies with pain as the primary presenting feature, and with poliomyelitis. There is therefore a small possibility that misdiagnosis of participants may have affected study inclusion, and that studies with mixed populations of participants that include both sensory, motor and combined sensory motor neuropathies as well as painful entrapment neuropathies or poliomyelitis were excluded. This could be a potential source of selection bias in the review. </p> </section> <section id="CD008146-sec-0088"> <h3 class="title" id="CD008146-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>There are currently no other systematic reviews of interventions for fatigue in peripheral neuropathy available, despite many treatments for fatigue including: drugs, pacing and grading of physical activity, general or specific exercise, compensatory strategies such as orthotics, relaxation, counselling, cognitive and educational strategies, either alone or as part of a multidimensional programme. </p> <section id="CD008146-sec-0089"> <h4 class="title">Systematic reviews of interventions for fatigue in other conditions</h4> <p>In the absence of evidence from reviews or high‐quality RCTs in peripheral neuropathy it may be helpful to consider the effect of interventions for fatigue in other conditions, including chronic fatigue syndrome (CFS), fibromyalgia, multiple sclerosis and cancer‐related fatigue. The high incidence of anxiety and depression in functional somatic syndromes such as fibromyalgia and CFS (<a href="./references#CD008146-bbs2-0032" title="HenningsenP , ZimmermannT , SattelH . Medically unexplained physical symptoms, anxiety, and depression: a meta‐analytic review. Psychosomatic Medicine2003;65(4):528‐33. ">Henningsen 2003</a>) and the specific pathophysiological features of multiple sclerosis and cancer‐related fatigue mean that recommendations from systematic reviews should be considered with caution. In all cases we included only evidence from Cochrane systematic reviews. </p> <section id="CD008146-sec-0090"> <h5 class="title">Drugs for fatigue</h5> <p>The evidence from Cochrane systematic reviews of drugs in the treatment of fatigue in other conditions was of varying quality. A systematic review of serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia indicated that they only provide a small improvement in fatigue (1.7% improvement) over placebo (<a href="./references#CD008146-bbs2-0031" title="HäuserW , UrrútiaG , TortS , ÜçeylerN , WalittB . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010292] ">Hauser 2013</a>). In reviews of amantadine or carnitine for fatigue in multiple sclerosis, the poor quality of the available RCTs meant that no conclusion regarding their efficacy could be drawn (<a href="./references#CD008146-bbs2-0052" title="PucciE , BrañasP , D'AmicoR , GiulianiG , SolariA , TausC . Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD002818.pub2] ">Pucci 2009</a>; <a href="./references#CD008146-bbs2-0059" title="TejaniAM , WasdellM , SpiwakR , RowellG , NathwaniS . Carnitine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD007280.pub3] ">Tejani 2012</a>). Finally, whilst the updated systematic review of drug therapy for the management of cancer‐related fatigue provides evidence that psychostimulant trials may give a clinically meaningful improvement in cancer‐related fatigue, new safety data indicate that the drugs are associated with increased adverse outcomes and they can no longer be recommended in the treatment of cancer‐related fatigue (<a href="./references#CD008146-bbs2-0047" title="MintonO , RichardsonA , SharpeM , HotopfM , StoneP . Drug therapy for the management of cancer‐related fatigue. Cochrane Database of Systematic Reviews2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] ">Minton 2010</a>). </p> </section> <section id="CD008146-sec-0091"> <h5 class="title">Non‐drug interventions for fatigue</h5> <p>We reviewed the evidence from recent Cochrane systematic reviews of non‐drug interventions for fatigue in other conditions, which suggests that exercise (<a href="./references#CD008146-bbs2-0022" title="EdmondsM , McGuireH , PriceJR . Exercise therapy for chronic fatigue syndrome. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003200.pub2] ">Edmonds 2004</a>) and cognitive behavioural therapy (CBT) (<a href="./references#CD008146-bbs2-0051" title="PriceJR , MitchellE , TidyE , HunotV . Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD001027.pub2] ">Price 2008</a>) for fatigue in CFS are both better than usual care, with the evidence for CBT being more extensive and robust than for exercise. In a review of exercise for treating fibromyalgia syndrome, there is very limited evidence that aerobic‐only exercise is likely to have no effect on fatigue in individuals with fibromyalgia (<a href="./references#CD008146-bbs2-0016" title="BuschAJ , BarberKA , OverendTJ , PelosoPMJ , SchachterCL . Exercise for treating fibromyalgia syndrome.. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003786.pub2] ">Busch 2007</a>). A systematic review of cognitive behavioural therapies for fibromyalgia concludes that there was only a 5.8% (95% CI 0.05 to 11.3) effect on fatigue (<a href="./references#CD008146-bbs2-0013" title="BernardyK , KloseP , BuschAJ , ChoyEHS , HäuserW . Cognitive behavioural therapies for fibromyalgia. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.CD009796.pub2] ">Bernardy 2013</a>). A systematic review of exercise for management of cancer‐related fatigue concluded that aerobic exercise is beneficial (<a href="./references#CD008146-bbs2-0020" title="CrampF , Byron‐DanielJ . Exercise for the management of cancer‐related fatigue in adults. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD006145.pub3] ">Cramp 2012</a>). </p> </section> <section id="CD008146-sec-0092"> <h5 class="title">Evidence from individual studies of interventions for fatigue in neuropathy</h5> <p>One article describing an uncontrolled case series of people with Charcot‐Marie‐Tooth disease 1A treated with modafinil for fatigue reported that all four participants had less fatigue within at least 10 days of commencing modafinil treatment (<a href="./references#CD008146-bbs2-0005" title="CarterGT , HanJJ , MayadevA , WeissMD . Modafinil reduces fatigue in Charcot‐Marie‐Tooth disease type 1A: a case series. American Journal of Hospice and Palliative Care2006;23(5):412‐6. ">Carter 2006</a>). The case study design means that this report has substantial risk of bias but may suggest that modafinil is a potentially useful drug for fatigue in people with Charcot‐Marie‐Tooth disease 1A, and merits well‐designed trials. </p> <p>The wide variety of causes and consequences in peripheral neuropathy, combined with a relatively low prevalence of individual conditions means that controlled trials of non‐drug interventions have been limited. In addition, despite the substantial prevalence of fatigue in people with peripheral neuropathy (<a href="./references#CD008146-bbs2-0046" title="MerkiesIS , SchmitzPI , SamijnJP , van derMechéFG , vanDoornPA . Fatigue in immune‐mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology1999;53(8):1648‐54. ">Merkies 1999</a>), subjective fatigue is not routinely evaluated in RCTs and other study designs of such interventions. However, one cohort study (<a href="./references#CD008146-bbs2-0027" title="GarssenMP , BussmannJB , SchmitzPI , ZandbergenA , WelterTG , MerkiesIS , et al. Physical training and fatigue, fitness, and quality of life in Guillain‐Barré syndrome and CIDP. Neurology2004;63(12):2393‐5. ">Garssen 2004</a>) and one case‐control study (<a href="./references#CD008146-bbs2-0030" title="GrahamRC , HughesRAC , WhiteCM . A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. Journal of Neurology2007;254(2):228‐35. ">Graham 2007</a>) of exercise for people with Guillain‐Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) reported significant reductions in fatigue after 12 weeks of either supervised aerobic cycling (<a href="./references#CD008146-bbs2-0027" title="GarssenMP , BussmannJB , SchmitzPI , ZandbergenA , WelterTG , MerkiesIS , et al. Physical training and fatigue, fitness, and quality of life in Guillain‐Barré syndrome and CIDP. Neurology2004;63(12):2393‐5. ">Garssen 2004</a>) or unsupervised community‐based exercise (<a href="./references#CD008146-bbs2-0030" title="GrahamRC , HughesRAC , WhiteCM . A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. Journal of Neurology2007;254(2):228‐35. ">Graham 2007</a>). Whilst these studies are subject to very high risks of bias due to their design, they may suggest that RCTs of exercise for people with fatigue due to peripheral neuropathy should be conducted. </p> </section> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008146-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias." data-id="CD008146-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.1 Change in fatigue &gt; 12 weeks after commencement of intervention at 12 months [VAS 0 ‐ 100)." data-id="CD008146-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.1 Change in fatigue &gt; 12 weeks after commencement of intervention at 12 months [VAS 0 ‐ 100). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Ascorbic acid versus placebo, outcome: 1.2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months) [seconds]." data-id="CD008146-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Ascorbic acid versus placebo, outcome: 1.2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months) [seconds]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.4 Change in physical function score of SF‐36." data-id="CD008146-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.4 Change in physical function score of SF‐36. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.6 Adverse events." data-id="CD008146-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ascorbic acid versus placebo, outcome: 2.6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ascorbic acid versus placebo, Outcome 1 Change in fatigue &gt; 12 weeks after commencement of intervention (measured at 12 to 24 months) (VAS 0 ‐ 10 or 0 ‐ 100)." data-id="CD008146-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ascorbic acid versus placebo, Outcome 1 Change in fatigue &gt; 12 weeks after commencement of intervention (measured at 12 to 24 months) (VAS 0 ‐ 10 or 0 ‐ 100). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ascorbic acid versus placebo, Outcome 2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months)." data-id="CD008146-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ascorbic acid versus placebo, Outcome 2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ascorbic acid versus placebo, Outcome 3 Change in speed of completion of 9 hole peg test &gt; 12 weeks after commencement of intervention (measured at 24 months)." data-id="CD008146-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ascorbic acid versus placebo, Outcome 3 Change in speed of completion of 9 hole peg test &gt; 12 weeks after commencement of intervention (measured at 24 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ascorbic acid versus placebo, Outcome 4 Change in physical function score of SF‐36 &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months)." data-id="CD008146-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ascorbic acid versus placebo, Outcome 4 Change in physical function score of SF‐36 &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ascorbic acid versus placebo, Outcome 5 Change in mental function score of SF‐36 &gt; 12 weeks after commencement of the intervention (measured at 12 months)." data-id="CD008146-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Ascorbic acid versus placebo, Outcome 5 Change in mental function score of SF‐36 &gt; 12 weeks after commencement of the intervention (measured at 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008146-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/urn:x-wiley:14651858:media:CD008146:CD008146-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_t/tCD008146-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ascorbic acid versus placebo, Outcome 6 Serious adverse events." data-id="CD008146-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Ascorbic acid versus placebo, Outcome 6 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/media/CDSR/CD008146/image_n/nCD008146-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008146-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Amantadine versus placebo for fatigue in Guillain‐Barré syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Amantadine versus placebo for fatigue in Guillain‐Barré syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fatigue in Guillain‐Barré syndrome<br/> <b>Settings:</b> <br/> <b>Intervention:</b> amantadine versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Amantadine </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in fatigue of at least 1‐point on the Fatigue Severity Scale between 4 to 12 weeks after commencement of intervention</b> <br/> Fatigue Severity Scale (FSS) from 1 to 7 (higher score is worse)<br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b> <br/> (71 to 318) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.56</b> <br/> (0.22 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 cross‐over study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in fatigue 12 or more weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in activity limitation 12 or more weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in participation 12 or more weeks after commencement of intervention using the</b> <br/> Rotterdam Handicap Scale. Scale from: 0 to 36.<br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in participation 12 or more weeks after commencement of intervention using the control group was<br/> <b>0.34 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in participation 12 or more weeks after commencement of intervention using the intervention group was<br/> <b>0.31 higher</b> <br/> (0.09 lower to 0.72 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74<br/> (1 cross‐over study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health related quality of life after 12 or more weeks or more after commencement of intervention</b> (not reported) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EHQ and SF‐36 measured but data not fully reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1 cross‐over study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 participants had serious adverse events in this study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Evidence downgraded two levels due to imprecision (small sample size and wide CI that crosses the line of no effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Amantadine versus placebo for fatigue in Guillain‐Barré syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008146-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ascorbic acid versus placebo for fatigue in peripheral neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ascorbic acid versus placebo for fatigue in peripheral neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with fatigue in peripheral neuropathy<br/> <b>Settings:</b> <br/> <b>Intervention:</b> ascorbic acid versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Ascorbic acid </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reduction in fatigue of at least 1 point on the Fatigue Severity Scale (FSS) between 4 to 12 weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in fatigue 12 or more weeks after commencement of intervention</b> <br/> Visual Analogue Scale (VAS) of fatigue<br/> Follow‐up: mean 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue 12 or more weeks after commencement of intervention in the intervention groups was<br/> <b>0.12 standard deviations lower</b> <br/> (0.32 lower to 0.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in activity limitation (ODSS/ONLS) 12 or more weeks after commencement of intervention</b> <br/> Overall Neuropathy Limitations Scale or Overall Disability Sum Score. Scale from: 0 to 12.<br/> Follow‐up: 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data available were not suitable for meta‐analysis</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in 10 metre timed walk 12 or more weeks after commencement of intervention</b> <br/> Time taken to walk 10 metres in seconds<br/> Follow‐up: 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean changes in 10 metre timed walk 12 or more weeks after commencement of intervention in the control groups were<b>a decrease of 0.40 seconds and an increase of 0.76 seconds</b><sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 10 metre timed walk 12 or more weeks after commencement of intervention in the intervention groups was <b>a decrease of</b> <br/> <b>0.39 seconds</b> (1.04 faster to 0.26 slower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in speed of completion of 9‐hole peg test (in seconds) 12 or more weeks after commencement of intervention</b> <br/> Time (in seconds) taken to complete 9‐hole peg test<br/> Follow‐up: mean 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in speed of completion of the 9‐hole peg test was an <b>increase of 0.85 seconds</b> in the control group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in speed of completion of the 9‐hole peg test was <b>a decrease of 0.74 seconds</b> </p> <p>(1.60 faster to 0.12 slower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life 12 or more weeks after commencement of the intervention</b> </p> <p><b>Change in SF‐36 physical function score</b> <br/> SF‐36 Physical Functioning Scale and Physical Component Score<br/> Follow‐up: 12‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life 12 or more weeks after commencement of the intervention (change in SF‐36 physical function score) in the intervention groups was<br/> <b>0.08 standard deviations higher</b> <br/> (0.12 lower to 0.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in participation 12 or more weeks after commencement of intervention</b> (not measured) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life 12 or more weeks after commencement of the intervention Change in mental function score of SF‐36</b> <br/> SF‐36 Mental Component Score<br/> Follow‐up: mean 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in health‐related quality of life 12 or more weeks after commencement of the intervention (change in mental function score of SF‐36) in the control group was <b>1.2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life 12 or more weeks after commencement of the intervention (change in mental function score of SF‐36) in the intervention groups was<br/> <b>0.9 higher</b> <br/> (2.65 lower to 4.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> <br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>76 per 1000</b> <br/> (42 to 137) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.70</b> <br/> (0.39 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>450<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Only one or two studies included.<br/> <sup>2</sup> Assumed control group risks are the control group values in the two trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Ascorbic acid versus placebo for fatigue in peripheral neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008146-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data and analysis: amantadine versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect estimate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in participation (using the Rotterdam Handicap Scale) &gt; 12 weeks after commencement of intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (cross‐over)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 [‐0.09 to 0.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Data and analysis: amantadine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/full#CD008146-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008146-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ascorbic acid versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in fatigue &gt; 12 weeks after commencement of intervention (measured at 12 to 24 months) (VAS 0 ‐ 10 or 0 ‐ 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.32, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in 10 m timed walk &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.04, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in speed of completion of 9 hole peg test &gt; 12 weeks after commencement of intervention (measured at 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in physical function score of SF‐36 &gt; 12 weeks after commencement of the intervention (measured at 12 to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.12, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in mental function score of SF‐36 &gt; 12 weeks after commencement of the intervention (measured at 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.39, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ascorbic acid versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008146.pub2/references#CD008146-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008146.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008146-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008146-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="pt#CD008146-note-0001">Português</a> </li> <li class="section-language"> <a class="" href="th#CD008146-note-0009">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008146\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008146\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008146\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008146\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008146\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008146.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008146.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008146.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008146.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008146.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716193643"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008146.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716193646"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008146.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d99889d521bf6',t:'MTc0MDcxNjE5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 